8-K: Leidos Reports Strong Q4 and Fiscal Year 2023 Results, Exceeding Guidance

• Leidos reported a revenue of $4.0 billion for the fourth quarter, an 8% increase year-over-year, and $15.4 billion for the full year, a 7% increase year-over-year.
• Diluted earnings per share (EPS) for the fourth quarter was $1.66, a 30% increase year-over-year, while full-year diluted EPS was $1.44, a 71% decrease year-over-year.
• Non-GAAP diluted EPS was $1.99 for the fourth quarter, a 9% increase year-over-year, and $7.30 for the full year, an 11% increase year-over-year.
• Cash flow from operations was $304 million for the fourth quarter and $1.2 billion for the full year.
• The company's backlog at the end of fiscal year 2023 was $37.0 billion, with $8.8 billion funded.
• Leidos is initiating fiscal year 2024 guidance with revenue between $15.7 and $16.1 billion, adjusted EBITDA margin in the mid-to-high 10% range, non-GAAP diluted EPS between $7.50 and $7.90, and approximately $1.1 billion in cash flows from operating activities.

Score: 7

Explanation: The sentiment is positive due to strong revenue growth, exceeding guidance, and increased non-GAAP earnings. However, the significant decrease in GAAP EPS and the large impairment charge temper the overall positive outlook.

• Leidos exceeded the high end of its guidance ranges for all metrics in the fourth quarter.
• The company demonstrated strong revenue growth across all customer segments, particularly in the Health segment.
• Improved program execution and reduced indirect spending contributed to increased earnings.
• The company saw increased volumes and higher incentive awards in the medical examination business.
• Leidos improved its Days Sales Outstanding (DSO) to 56 days, a 2-day improvement from the fourth quarter of fiscal year 2022.
• The company returned $253 million to shareholders through share repurchases and dividends.
• The company's new operating structure is expected to drive future growth.

• Full-year diluted EPS decreased by 71% year-over-year, primarily due to pre-tax impairment and restructuring charges of $699 million related to the Security Enterprise Solutions (SES) reporting unit.
• Net income margin for the year decreased to 1.3% from 4.8% in fiscal year 2022.
• The Civil segment experienced a significant decline in operating income margin for the year, primarily due to impairment and restructuring charges.

• The company's future performance is subject to developments in U.S. government defense and non-defense budgets.
• Uncertainties in tax due to new tax legislation or other regulatory developments could impact results.
• Deterioration of economic conditions or weakening in credit or capital markets could affect the company.
• The company faces risks related to delays in the U.S. government contract procurement process.
• The company's ability to attract and retain skilled employees is a risk factor.
• The company is exposed to cybersecurity, data security, and other security threats.
• The company's ability to grow its commercial health and infrastructure businesses could be negatively affected by budgetary constraints.
• The company's forward guidance for cash flows provided by operating activities is subject to the impact of the Tax Cuts and Jobs Act of 2017 provision requiring the capitalization and amortization of research and development costs.

Leidos is initiating fiscal year 2024 guidance with revenue between $15.7 and $16.1 billion, adjusted EBITDA margin in the mid-to-high 10% range, non-GAAP diluted EPS between $7.50 and $7.90, and approximately $1.1 billion in cash flows from operating activities.

• Leidos delivered on all of its financial commitments with a strong finish to the year.
• Record topand bottom-line performance enabled the company to exceed the high end of the guidance ranges.
• The team has enhanced its focus on cost controls and cash generation.
• 2024 is going to be another busy and exciting year for Leidos, as the company capitalizes on its leaner, more focused organizational structure.

Leidos operates in the national security and health sectors, which are heavily influenced by government spending and technological advancements. The company's performance reflects the demand for its services in these sectors, particularly in areas like digital modernization and health services. The new operating structure is designed to better align with customer needs and market opportunities.

• Leidos' revenue growth of 7% for the year is solid, but it is important to compare this to peers such as General Dynamics (GD), Lockheed Martin (LMT), and Northrop Grumman (NOC), which also operate in the defense and government services sectors.
• The 71% decrease in diluted EPS is concerning and is primarily due to a large impairment charge, which is not typical for companies in this sector. This should be compared to the EPS performance of peers to understand if this is an industry-wide issue or specific to Leidos.
• The non-GAAP EPS growth of 11% is a positive sign and should be compared to the non-GAAP EPS growth of peers to assess Leidos' operational performance.
• The adjusted EBITDA margin of 10.8% for the year is within the range of industry standards, but it is important to compare this to the margins of peers to understand Leidos' profitability relative to its competitors.
• The backlog of $37 billion is a strong indicator of future revenue, but it is important to compare this to the backlog of peers to understand Leidos' competitive position.
• The company's FY24 guidance is consistent with its 2021 Investor Day targets, which is a positive sign of management's ability to execute its strategy. This should be compared to the guidance of peers to understand Leidos' growth prospects relative to its competitors.

• Shareholders will benefit from the increased revenue, non-GAAP earnings, and share repurchases.
• Employees may benefit from the company's growth and improved financial performance.
• Customers will benefit from the company's focus on delivering innovative solutions.
• Suppliers and creditors will benefit from the company's strong financial position.

• Leidos will continue to execute its business plan and long-term management initiatives.
• The company will focus on capitalizing on its leaner, more focused organizational structure.
• Leidos will continue to monitor and manage risks associated with its business.

• December 30, 2022: End of fiscal year 2022.
• October 30, 2022: Completion of the acquisition of Cobham Special Missions.
• December 29, 2023: End of fiscal year 2023.
• December 30, 2023: Implementation of a new operating and reporting structure.
• February 8, 2024: Leidos Board of Directors declared a cash dividend.
• February 13, 2024: Date of the earnings release and conference call.
• March 15, 2024: Record date for the cash dividend.
• March 28, 2024: Payment date for the cash dividend.
• February 13, 2025: Archived version of the webcast will be available until this date.